Acura's methamphetamine-resistant Nexafed now patent-protected

PALATINE, Ill. — Acura Pharmaceuticals on Monday announced that the company has been issued its first U.S. patent directed at the company's Impede technology and products utilizing that technology. 

 

Impede technology is a polymer matrix that disrupts the conversion of pseuodephedrine into methamphetamine. The technology is incorporated in Acura's marketed product Nexafed (pseudoephedrine HCl) tablets — a methamphetamine-resistant product — and the soon-to-be-launched Nexafed Pressure and Pain (pseudoephedrine HCl and acetaminophen) product.

 

There is growing evidence suggesting that when pharmacies replace traditional single ingredient pseudoephedrine products with meth-resistant products like Nexafed, there is a measurable decrease in local methamphetamine production, Acura stated.